Levothyroxine Dose Requirements in a Thyroid Cancer-Predominant Cohort: A Target-Aware Analysis of Gastrointestinal and Medication-Related Factors

Background/Objectives: In thyroid cancer, high levothyroxine (LT4) doses may reflect intentional thyroid-stimulating hormone (TSH) suppression rather than impaired bioavailability. We assessed gastrointestinal and medication-related factors in relation to LT4 dose after accounting for treatment goals and body mass index (BMI). Methods: This cross-sectional study included 218 LT4-treated patients and 69 non-LT4 reference patients. A structured questionnaire captured gastrointestinal symptoms, comorbidities, medications, and administration timing. BMI was calculated from recorded height and weight. The main adjusted analysis was restricted to participants with clinician-assessed target achievement; exploratory models additionally used measured TSH categories. Multivariable models used HC3 robust standard errors. Results: Among LT4-treated patients, 201 (92.2%) had thyroid cancer, 81 (37.2%) reported gastrointestinal symptoms, 74 (33.9%) had at least one potential interfering factor, and 49 (22.5%) reported proton-pump inhibitor (PPI) use. Factor prevalence was comparable in the reference population after adjustment for age, sex, and BMI. In the BMI-adjusted model (n = 156), PPI use was not associated with higher LT4 dose (β = −0.031 µg/kg/day, 95% CI −0.193 to 0.131; p = 0.703). Intended TSH suppression was associated with higher dose (β = 0.420, 95% CI 0.269–0.570; p < 0.001), whereas BMI was inversely associated with dose per kilogram. An exploratory BMI-adjusted model accounting for measured TSH categories also showed no significant association with PPI exposure (n = 184, β = 0.024 µg/kg/day, 95% CI −0.122 to 0.169; p = 0.751). Conclusions: Potentially interfering factors were common but were not independently associated with higher dose requirements. LT4 dose in thyroid cancer should be interpreted in relation to therapeutic intent and anthropometry; PPI exposure alone was not a reliable marker of increased dose requirement.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-18
DOI
https://doi.org/10.3390/jcm15229032
Primary Topic
Thyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Levothyroxine Dose Requirements in a Thyroid Cancer-Predominant Cohort: A Target-Aware Analysis of Gastrointestinal and Medication-Related Factors

Friederike Eilsberger, Wadim Bowl, Markus Luster, Ali Ebrahimifard et al.
3 links
Journal of Clinical Medicine
Thyroid Disorders and Treatments
article

Levothyroxine Dose Requirements in a Thyroid Cancer-Predominant Cohort: A Target-Aware Analysis of Gastrointestinal and Medication-Related Factors

Friederike Eilsberger, Wadim Bowl, Markus Luster, Ali Ebrahimifard, Conrad‐Amadeus Voltin, Shamim Bagheri, Andreas Pfestroff, Pietro De Fazio, Anne-Sophie Schmidt, Behrooz H. Yousefi
article en

Abstract

Background/Objectives: In thyroid cancer, high levothyroxine (LT4) doses may reflect intentional thyroid-stimulating hormone (TSH) suppression rather than impaired bioavailability. We assessed gastrointestinal and medication-related factors in relation to LT4 dose after accounting for treatment goals and body mass index (BMI). Methods: This cross-sectional study included 218 LT4-treated patients and 69 non-LT4 reference patients. A structured questionnaire captured gastrointestinal symptoms, comorbidities, medications, and administration timing. BMI was calculated from recorded height and weight. The main adjusted analysis was restricted to participants with clinician-assessed target achievement; exploratory models additionally used measured TSH categories. Multivariable models used HC3 robust standard errors. Results: Among LT4-treated patients, 201 (92.2%) had thyroid cancer, 81 (37.2%) reported gastrointestinal symptoms, 74 (33.9%) had at least one potential interfering factor, and 49 (22.5%) reported proton-pump inhibitor (PPI) use. Factor prevalence was comparable in the reference population after adjustment for age, sex, and BMI. In the BMI-adjusted model (n = 156), PPI use was not associated with higher LT4 dose (β = −0.031 µg/kg/day, 95% CI −0.193 to 0.131; p = 0.703). Intended TSH suppression was associated with higher dose (β = 0.420, 95% CI 0.269–0.570; p < 0.001), whereas BMI was inversely associated with dose per kilogram. An exploratory BMI-adjusted model accounting for measured TSH categories also showed no significant association with PPI exposure (n = 184, β = 0.024 µg/kg/day, 95% CI −0.122 to 0.169; p = 0.751). Conclusions: Potentially interfering factors were common but were not independently associated with higher dose requirements. LT4 dose in thyroid cancer should be interpreted in relation to therapeutic intent and anthropometry; PPI exposure alone was not a reliable marker of increased dose requirement.

Journal of Clinical MedicineVol. 15(22)
Philipps University of Marburg (DE), University of Cologne (DE)
Good health and well-being
Thyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon